Sinolink: Focus on the ADA annual meeting in late June, balancing changes in Medical consumption demand as summer approaches.
Continue to have strong confidence that the pharmaceutical Sector will reverse its trend in 2025, with innovative drugs as the main focus and the left-side Sector's difficulties reversing still being the biggest investment opportunity in the pharmaceutical Sector for 2025.
CICC: The abundance of funds in the Hong Kong stock market and the scarcity of Assets.
CICC believes that the "abundance of funds" due to excessive liquidity and the "lack of assets" with limited returns will inevitably lead to overall Index trends being difficult to find, resulting in range-bound fluctuations, while structural market trends will flourish. Currently, the overall macro and market environment in China still needs repair but has structural highlights that are more favorable for Hong Kong stocks. This is because whether it is providing stable returns through dividends, or representing the mainline of structural opportunities such as new consumption, AI Technology, or even innovative drugs, Hong Kong stocks have a greater advantage, which also explains the outperformance of the Hong Kong stock market.
Angel Align (06699.HK) received a Shareholding of 0.3137 million shares of ordinary stock from JPMorgan, valued at approximately 17.4575 million Hong Kong dollars.
On June 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on June 9, JPMorgan (JPMorgan Chase & Co.) increased its shareholding in $Jiangsu Tianyi (06699.HK)$ by 313,700 ordinary shares at an average on-market price of HKD 55.6573 per share and an off-market average price of HKD 55.5716 per share, totaling approximately HKD 17.4575 million. After the increase, JPMorgan's latest holdings amount to 12.2142 million shares, with the shareholding ratio rising from 6.99% to 7.18%. Image source: Hong Kong Stock Exchange equity disclosure What is equity.
One Angelalign Technology Insider Has Reduced Their Stake
Angelalign (06699.HK): Global layout drives revenue growth and profits steadily rise.
Event: On March 20, 2025, the company released the 2024 annual report, achieving total operating revenue of 1.932 billion yuan in 2024, a year-on-year increase of 28.2%, with net income attributable to shareholders of 87.0803 million yuan, year-on-year.
ANGELALIGN To Go Ex-Dividend On May 27th, 2025 With 0.38 HKD Special Dividend Per Share
May 23rd (Beijing Time) - $ANGELALIGN(06699.HK)$ is trading ex-dividend on May 27th, 2025.Shareholders of record on May 28th, 2025 will receive 0.38 HKD special dividend per share on June 20th, 2025.
【Brokerage Focus】CMB International gives a first-time "Buy" rating for Time Angel (06699) and is Bullish on the strong growth of overseas Business.
Jinwu Financial News | According to a Research Report from CCB International, Angelalign (06699), established in 2003, is a leading provider of invisible correction solutions in China. Since 2021, it has been the number one brand in the Chinese invisible correction market for four consecutive years. The company's revenue compound annual growth rate from 2019 to 2024 is as high as 23.8% (calculated in US dollars based on historical exchange rates). The bank expects the company to benefit from improvements in the domestic competition environment and rapid expansion in overseas markets, continuing to maintain rapid growth. The compound annual growth rate of revenue is expected to reach 18.0% from 2024 to 2027. The bank believes that,
The reshuffling in the medical aesthetics sector is underway: the "three musketeers" of hyaluronic acid are losing momentum while the "twin heroines" of collagen are rising.
① Since 2025, the stock prices of Giant Biotechnology and Jinbo Biotechnology have increased by 70.14% and 131.84% respectively. ② Founder Securities pointed out that the supply-side bonus period for hyaluronic acid has ended, leading to oversupply and excess capacity. ③ CITIC SEC believes that the prosperity of the collagen Industry will continue, and attention should be paid to opportunities for leading companies.
ANGELALIGN(6699.HK):DOMESTIC CLEAR ALIGNER LEADER ACCELERATING GLOBAL EXPANSION
The Concept of ergotamine has driven beauty care stations to a peak, beware of the risks of high-positioned collective stocks retreating.
Track the entire lifecycle of the main Sector.
Angelalign Technology Inc. Announces Key Leadership Changes
The Senior Vice President of Angelalign (06699.HK) has resigned.
Angelalign (06699.HK) announced that Zhu Lingbo has resigned from the positions of Senior Vice President, Secretary of the Board of Directors, Company Secretary, and Authorized Representative, effective from May 15, 2025.
Angel Align (06699) appointed Li Liangxian as the company secretary and authorized representative.
Angelalign Technology (06699) announced that Mr. Zhu Lingbo has resigned from the company's Senior Vice President and Board of Directors Secretary, Company Secretary...
Angelalign (06699.HK): The launch of new products is expected to further strengthen competitive advantages, with strong momentum for long-term development.
Event summary: In April 2025, Angelalign announced that its children's caries prevention invisible aligner will be fully launched in dental clinics across the country. This product utilizes material technology innovation to provide children with comprehensive and lasting prevention while correcting their teeth.
Angelalign (6699.HK): In 2024, the number of overseas cases is expected to grow rapidly as China's leading clear orthodontics brand goes international.
Key points: The company released its 2024 annual report, meeting market expectations. In 2024, the company achieved revenue of 0.269 billion dollars, a year-on-year increase of 28.2%; adjusted Net income was 26.86 million dollars, a year-on-year increase of 2.9%; net.
Angelalign (6699.HK): Continued deepening of overseas布局, new products released in the field of early orthodontics for children.
Performance Summary: The company released its 2024 annual report, achieving revenue of $268.8 million / +28.2%, net income of $10 million / +46.6%, and adjusted net income of $26.9 million.
Angelalign Technology Inc. Issues Supplemental Announcement on Connected Transactions
Hong Kong stocks change | Angelalign Technology (06699) rises over 4%. Shareholder Hua Li has acquired 40% equity of Shanghai Kaihao.
Angelalign (06699) rose over 4%. As of the time of writing, it has increased by 3.88%, trading at 50.85 Hong Kong dollars, with a transaction volume of 16.3812 million Hong Kong dollars.
Angelalign Technology Announces 2025 AGM Details
ANGELALIGN: 2024 ANNUAL REPORT